Beginning in the summer, cheaper, 15-minute tests — which detect viral proteins called antigens on a nasal swab — became available. The first versions still needed to be processed using portable readers. The millions of new tests from Abbott Laboratories now going out to states are even easier to use: they’re about the size of a credit card and can be developed with a few drops of chemical solution.
Federal health officials say about half of the nation’s daily testing capacity now consists of rapid tests.
Large hospitals and laboratories electronically feed their results to state health departments, but there is no standardized way to report the rapid tests that are often done elsewhere. And state officials have often been unable to track where these tests are being shipped and whether results are being reported.
In Minnesota, officials created a special team to try and get more testing data from nursing homes, schools and other newer testing sites, only to be deluged by faxes and paper files.
“It’s definitely a challenge because now we have to do many more things manually than we were with electronic reporting,” said Kristen Ehresmann, of the Minnesota Department of Health.
Even before Abbott's newest BinaxNOW rapid tests hit the market last month, undercounting was a concern.
Competitors Quidel and Becton Dickinson have together shipped well over 35 million of their own quick tests since June. But that massive influx of tests hasn't showed up in national testing numbers, which have mostly ranged between 750,000 and 950,000 daily tests for months.
Besides tallying new cases, COVID-19 testing numbers are used to calculate a key metric on the outbreak: the percentage of tests positive for COVID-19. The World Health Organization recommends countries test enough people to drive their percent of positives below 5%. And the U.S. has mostly been hovering around or below that rate since mid-September, a point that President Donald Trump and his top aides have touted to argue that the nation has turned the corner on the outbreak. The figure is down from a peak of 22% in April.
But some disease-tracking specialists are skeptical. Engel said his group's members think they aren't getting all the results.
“So it may be a false conclusion,” he said.
One of the challenges to an accurate count: States have wildly different approaches. Some states lump all types of tests together in one report, some don't tabulate the quick antigen tests at all and others don't publicize their system. Because antigen tests are more prone to false negatives and sometimes require retesting, most health experts say they should be recorded and analyzed separately. But currently the vast majority of states do not do that and post the results online.
The federal government is allocating the tests to states based on their population, rather than helping them develop a strategy based on the size and severity of their outbreaks.
“That’s just lazy” said Dr. Michael Mina of Harvard University. “Most states won’t have the expertise to figure out how to use these most appropriately.”
Instead, Mina said the federal government should direct the limited test supplies to key hot spots around the country, driving down infections in the hardest-hit communities. Keeping tighter control would also ensure test results are quickly reported.
Johns Hopkins University researcher Gigi Gronvall agrees health officials need to carefully consider where and when to deploy the tests. Eventually, methods for tracking the tests will catch up, she said.
“I think having the tools to determine if someone is infectious is a higher priority," she said.
AP data journalist Nicky Forster contributed to this story
Follow Matthew Perrone on Twitter: @AP_FDAwriter
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
FILE - In this July 14, 2020, file photo, people wait in line for coronavirus testing at Dodger Stadium in Los Angeles. After months of struggling to ramp up coronavirus testing, the U.S. is now capable of testing some 3 million people daily thanks to a growing supply of rapid tests. But the testing boom comes with a new challenge: keeping track of the results. (AP Photo/Mark J. Terrill, File)
Credit: Mark J. Terrill
Credit: Mark J. Terrill
FILE - This image provided by Abbott Laboratories in August 2020 shows the company's BinaxNOW rapid COVID-19 nasal swab test. After months of struggling to ramp up coronavirus testing, the U.S. is now capable of testing some 3 million people daily thanks to a growing supply of rapid tests. But the testing boom comes with a new challenge: keeping track of the results. (Abbott Laboratories via AP)